93470-27-0

Usage

Uses

Used in the Production of Polyurethane Resins:
(S)-(+)-1-CYCLOHEXYLETHYL ISOCYANATE is used as a key component in the production of polyurethane resins. These resins are versatile materials that find applications in various industries due to their unique properties.
Used in the Manufacturing Industry:
In the manufacturing industry, (S)-(+)-1-CYCLOHEXYLETHYL ISOCYANATE is used as a raw material for creating polyurethane-based products. These products include foams, which are utilized in furniture, bedding, and insulation materials, due to their lightweight and durable nature.
Used in the Adhesives and Sealants Industry:
(S)-(+)-1-CYCLOHEXYLETHYL ISOCYANATE is used as a component in the formulation of adhesives and sealants. The resulting polyurethane resins provide strong bonding and sealing properties, making them suitable for construction, automotive, and various other applications.
Used in the Coatings Industry:
In the coatings industry, (S)-(+)-1-CYCLOHEXYLETHYL ISOCYANATE is used to produce polyurethane coatings. These coatings offer excellent durability, flexibility, and resistance to wear and tear, making them ideal for use in wood, metal, and plastic coatings.

InChI:InChI=1/C9H15NO/c1-8(10-7-11)9-5-3-2-4-6-9/h8-9H,2-6H2,1H3/t8-/m0/s1

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 5913-13-3 [(1R)-1-cyclohexylethyl]amine 
• 503-38-8 trichloromethyl chloroformate 
• 17430-98-7 [(1S)-1-cyclohexylethyl]amine 
• 4352-49-2 1-cyclohexylethylamine 
• 854885-85-1 ethyl (1-cyclohexylethyl)carbamate 

Downstream Products

• 97722-66-2 Bis-<1-cyclohexyl-aethyl>-carbodiimid 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of making these compounds or pharmaceutically acceptable sal

PROLINE UREA CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION

Compounds of the formulae (I) and (II) are disclosed. The compounds are CCRl antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.

Influence of bulky substituents on histamine H3 receptor agonist/antagonist properties

Novel derivatives of 3-(1H-imidazol-4-yl)propanol were designed on the basis of lead compounds belonging to the carbamate or ether series possessing (partial) agonist properties on screening assays of the histamine H3 receptor. One pair of enantiomers in the series of α-methyl-branched chiral carbamates was stereoselectively prepared in high optical yields. Enantiomeric purity was checked by Mosher amide derivatives of precursors and capillary electrophoresis of the final compounds with trimethyl-β-cyclodextrin as chiral selector, and was determined to be ≥95%. The novel compounds were investigated in various histamine H3 receptor assays in vitro and in vivo. Some compounds displayed partial agonist activity on synaptosomes of rat brain cortex, whereas others exhibited antagonist properties only. Selected compounds were investigated in [125I]iodoproxyfan binding studies on the human histamine H3 receptor and showed high affinity in the nanomolar concentration range. Under in vivo conditions after oral administration to mice, some of the compounds exhibited partial or full agonist activity in the brain at low dosages. The (S)-enantiomer of one pair of chiral carbamates (9) proved to be the eutomer; thus, the (S)-enantiomer was selected for further pharmacological studies. In a peripheral in vivo test model in rats, measuring the level of inhibition of capsaicin-induced plasma extravasation, (S)-9 again proved its high oral agonist potency with full intrinsic activity (ED50 values of 0.07-0.1 mg/kg depending on tissue).